> top > docs > PubMed:33754144 > annotations

PubMed:33754144 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-192 Sentence denotes Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.
T2 193-204 Sentence denotes BACKGROUND:
T3 205-397 Sentence denotes In patients with COVID-19, granulocyte-macrophage colony stimulating factor (GM-CSF) might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death.
T4 398-577 Sentence denotes We aimed to evaluate whether mavrilimumab, a monoclonal antibody to the GM-CSF receptor, would improve outcomes in patients with COVID-19 pneumonia and systemic hyperinflammation.
T5 578-586 Sentence denotes METHODS:
T6 587-699 Sentence denotes This investigator-initiated, multicentre, double-blind, randomised trial was done at seven hospitals in the USA.
T7 700-828 Sentence denotes Inclusion required hospitalisation, COVID-19 pneumonia, hypoxaemia, and a C-reactive protein concentration of more than 5 mg/dL.
T8 829-892 Sentence denotes Patients were excluded if they required mechanical ventilation.
T9 893-1057 Sentence denotes Patients were randomly assigned (1:1) centrally, with stratification by hospital site, to receive mavrilimumab 6 mg/kg as a single intravenous infusion, or placebo.
T10 1058-1147 Sentence denotes Participants and all clinical and research personnel were masked to treatment assignment.
T11 1148-1252 Sentence denotes The primary endpoint was the proportion of patients alive and off supplemental oxygen therapy at day 14.
T12 1253-1335 Sentence denotes The primary outcome and safety were analysed in the intention-to-treat population.
T13 1336-1426 Sentence denotes This trial is registered at ClinicalTrials.gov, NCT04399980, NCT04463004, and NCT04492514.
T14 1427-1436 Sentence denotes FINDINGS:
T15 1437-1560 Sentence denotes Between May 28 and Sept 15, 2020, 40 patients were enrolled and randomly assigned to mavrilimumab (n=21) or placebo (n=19).
T16 1561-1712 Sentence denotes A trial of 60 patients was planned, but given slow enrolment, the study was stopped early to inform the natural history and potential treatment effect.
T17 1713-1915 Sentence denotes At day 14, 12 (57%) patients in the mavrilimumab group were alive and off supplemental oxygen therapy compared with nine (47%) patients in the placebo group (odds ratio 1·48 [95% CI 0·43-5·16]; p=0·76).
T18 1916-2003 Sentence denotes There were no treatment-related deaths, and adverse events were similar between groups.
T19 2004-2019 Sentence denotes INTERPRETATION:
T20 2020-2294 Sentence denotes There was no significant difference in the proportion of patients alive and off oxygen therapy at day 14, although benefit or harm of mavrilimumab therapy in this patient population remains possible given the wide confidence intervals, and larger trials should be completed.
T21 2295-2303 Sentence denotes FUNDING:
T22 2304-2328 Sentence denotes Kiniksa Pharmaceuticals.
T1 0-192 Sentence denotes Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.
T2 193-204 Sentence denotes BACKGROUND:
T3 205-397 Sentence denotes In patients with COVID-19, granulocyte-macrophage colony stimulating factor (GM-CSF) might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death.
T4 398-577 Sentence denotes We aimed to evaluate whether mavrilimumab, a monoclonal antibody to the GM-CSF receptor, would improve outcomes in patients with COVID-19 pneumonia and systemic hyperinflammation.
T5 578-586 Sentence denotes METHODS:
T6 587-699 Sentence denotes This investigator-initiated, multicentre, double-blind, randomised trial was done at seven hospitals in the USA.
T7 700-828 Sentence denotes Inclusion required hospitalisation, COVID-19 pneumonia, hypoxaemia, and a C-reactive protein concentration of more than 5 mg/dL.
T8 829-892 Sentence denotes Patients were excluded if they required mechanical ventilation.
T9 893-1057 Sentence denotes Patients were randomly assigned (1:1) centrally, with stratification by hospital site, to receive mavrilimumab 6 mg/kg as a single intravenous infusion, or placebo.
T10 1058-1147 Sentence denotes Participants and all clinical and research personnel were masked to treatment assignment.
T11 1148-1252 Sentence denotes The primary endpoint was the proportion of patients alive and off supplemental oxygen therapy at day 14.
T12 1253-1335 Sentence denotes The primary outcome and safety were analysed in the intention-to-treat population.
T13 1336-1426 Sentence denotes This trial is registered at ClinicalTrials.gov, NCT04399980, NCT04463004, and NCT04492514.
T14 1427-1436 Sentence denotes FINDINGS:
T15 1437-1560 Sentence denotes Between May 28 and Sept 15, 2020, 40 patients were enrolled and randomly assigned to mavrilimumab (n=21) or placebo (n=19).
T16 1561-1712 Sentence denotes A trial of 60 patients was planned, but given slow enrolment, the study was stopped early to inform the natural history and potential treatment effect.
T17 1713-1915 Sentence denotes At day 14, 12 (57%) patients in the mavrilimumab group were alive and off supplemental oxygen therapy compared with nine (47%) patients in the placebo group (odds ratio 1·48 [95% CI 0·43-5·16]; p=0·76).
T18 1916-2003 Sentence denotes There were no treatment-related deaths, and adverse events were similar between groups.
T19 2004-2019 Sentence denotes INTERPRETATION:
T20 2020-2294 Sentence denotes There was no significant difference in the proportion of patients alive and off oxygen therapy at day 14, although benefit or harm of mavrilimumab therapy in this patient population remains possible given the wide confidence intervals, and larger trials should be completed.
T21 2295-2303 Sentence denotes FUNDING:
T22 2304-2328 Sentence denotes Kiniksa Pharmaceuticals.

yangbin123xm_800_3

Id Subject Object Predicate Lexical cue
T1 37-55 DP denotes COVID-19 pneumonia
T2 527-545 DP denotes COVID-19 pneumonia
T3 736-754 DP denotes COVID-19 pneumonia
T4 0-12 CI denotes Mavrilimumab
T5 991-1003 CI denotes mavrilimumab
T6 427-439 CI denotes mavrilimumab
T7 1522-1534 CI denotes mavrilimumab
T8 1749-1761 CI denotes mavrilimumab
T9 2154-2166 CI denotes mavrilimumab
T10 1049-1056 CI denotes placebo
T12 1545-1552 CI denotes placebo
T13 1856-1863 CI denotes placebo

chenxin_473849_800_3

Id Subject Object Predicate Lexical cue
T10 2154-2166 CI denotes mavrilimumab
T11 1049-1056 CI denotes placebo
T13 1545-1552 CI denotes placebo
T14 1856-1863 CI denotes placebo
T5 0-12 CI denotes Mavrilimumab
T6 991-1003 CI denotes mavrilimumab
T7 427-439 CI denotes mavrilimumab
T8 1522-1534 CI denotes mavrilimumab
T9 1749-1761 CI denotes mavrilimumab
T15 37-55 DP denotes COVID-19 pneumonia
T16 527-545 DP denotes COVID-19 pneumonia
T17 736-754 DP denotes COVID-19 pneumonia